Cortical microstructural MRI for detection of early target engagement in AD drug trials: post-hoc analysis of exploratory outcomes from a Phase 1b safety study for XPro1595 in AD
Improvements in gray matter (GM) occurred in regions most affected by amyloid-beta aggregation in early and late stages of Alzheimer’s disease. This signals early, disease-specific XPro target engagement in the most affected regions
Clinical and biomarker correlates of region-specific diffusion MRI metrics in a short-term, Phase 1b clinical trial for XPro1595 in Alzheimer’s disease
Improvements in GM in these regions were associated with improvements in white matter (WM) in the WM bundle (the bilateral cingulum) that is functionally and/or anatomically connected to the GM regions in question. This finding indicates an early treatment effect for XPro1595 on both neuroinflammation and neurodegeneration in Alzheimer’s disease.